Vectura rated a buy by Jefferies

Jefferies & Co., Inc. analyst Robin Campbell gave Vectura Group a buy rating. A run on deals, with more expected, makes the company an attractive investment given its drug development expertise and state-of-the-art dry powder inhalers for treating diseases. Vectura is one of the analyst's top picks in the Euro Life Sciences space. Shares of the Wiltshire, U.K.-based pharmaceutical company were down 0.75p, or 0.84%, at 88.25p. (London: VEC)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.